Yahoo Web Search

Search results

1. finance.yahoo.com › news › astrazenecas-medimmuneAstraZeneca's Medimmune Terminates DNA Cancer ... - Yahoo Finance

   finance.yahoo.com › news › astrazenecas-medimmune

   • Cached

   Nov 1, 2021 · MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine development program agreement. Under the ...

2. finance.yahoo.com › news › bioasis-enters-licensebiOasis Enters Into a License Agreement With Medimmune for ...

   finance.yahoo.com › news › bioasis-enters-license

   • Cached

   Mar 17, 2014 · Under the terms of the agreement, MedImmune will evaluate the therapeutic effect of its pre-clinical assets with next-generation versions of biOasis's Transcend brain delivery platform.

3. www.biopharmadive.com › news › astrazeneca-retiresAstraZeneca retires Medimmune name amid sales turnaround

   www.biopharmadive.com › news › astrazeneca-retires

   • Cached

   Feb 14, 2019 · Yet several MedImmune-developed drugs will be key to AstraZeneca’s return to growth, including the PD-L1 inhibitor Imfinzi (durvalumab) and the asthma therapy Fasenra (benralizumab). AstraZeneca recorded $633 million in Imfinzi sales for 2018, and now expects peak U.S. sales of at least $1 billion. Fasenra, meanwhile, fetched $297 million ...

4. finance.yahoo.com › news › astrazenecas-medimmuneAstraZeneca's MedImmune unit acquires AlphaCore Pharma

   finance.yahoo.com › news › astrazenecas-medimmune

   • Cached

   Apr 3, 2013 · AstraZeneca announced that MedImmune, its global biologics research and development unit, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the ...

5. pharmaphorum.com › news › medimmune-completes-500mMedImmune completes $500m acquisition of Amplimmune

   pharmaphorum.com › news › medimmune-completes-500m

   • Cached

   Oct 8, 2013 · Under terms of the acquisition, MedImmune will own 100% of Amplimmune's shares for an initial consideration of $225 million and deferred consideration of up to $275 million based on reaching ...

6. www.pharmatimes.com › news › astrazeneca_revels_inAstraZeneca revels in MedImmune buy and oncology pipeline

   www.pharmatimes.com › news › astrazeneca_revels_in

   Jun 6, 2007 · PharmaTimes Media Ltd. Mansard House Church Road Little Bookham Leatherhead Surrey KT23 3JG. E: editorial@pharmatimes.com E: subscriptions@pharmatimes.com T: +44 (0)20 7240 6999 F: +44 (0)20 7240 4479. When completed, AstraZeneca’s $15.6 billion acquisition of MedImmune will realise the firm’s long-stated goal of becoming a true biologics ...

7. People also ask

   Will AstraZeneca buy MedImmune?

   • When completed, AstraZeneca’s $15.6 billion acquisition of MedImmune will realise the firm’s long-stated goal of becoming a true biologics company, according to Charles Morris, vice president of clinical development, oncology.

   AstraZeneca revels in MedImmune buy and oncology pipeline

   www.pharmatimes.com/news/astrazeneca_revels_in_medimmune_buy_and_oncology_pipeline_990050/

   See all results for this question

   Who is MedImmune?

   • We’re an industry leader in personalized medicine – developing new products that may allow doctors to prescribe a specific, customized treatment for each patient’s individual needs. Renowned for originality and creativity, and backed by a 20-year heritage, MedImmune is synonymous with intelligent risk-taking and accountability.

   Medimmune UK Ltd Liverpool, Renaissiance Way, Speke Boulevard

   liverpool.cylex-uk.co.uk/company/medimmune-uk-ltd-13454557.html

   See all results for this question

   Why did AstraZeneca retire MedImmune?

   • After 30 years of drug development, MedImmune will cease to exist as an industry name now that owner AstraZeneca has decided to retire the brand as part of ongoing restructuring efforts. The decision comes a little more than a month after AstraZeneca announced organizational changes meant to bolster its R&D and commercial efforts.

   AstraZeneca retires Medimmune name amid sales turnaround

   www.biopharmadive.com/news/astrazeneca-retires-medimmune-name-amid-sales-turnaround/548489/

   See all results for this question

8. www.marketwatch.com › story › astrazeneca-to-buyAstraZeneca to buy MedImmune for $15.6 billion - MarketWatch

   www.marketwatch.com › story › astrazeneca-to-buy

   Apr 23, 2007 · Under the terms of the deal, AstraZeneca AZN, -0.84% (AZN) has agreed to pay $58 a share for MedImmune, MEDI, -0.58% or a 53% premium over MedImmune's stock price right before it announced it was ...